Total Payments
$173,649
2024 Payments
$4,816
Companies
11
Transactions
217
Payment Breakdown by Category
Other$118,161 (68.0%)
Travel$32,017 (18.4%)
Consulting$16,550 (9.5%)
Food & Beverage$5,391 (3.1%)
Research$1,530 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $71,788 | 28 | 41.3% |
| Honoraria | $46,373 | 21 | 26.7% |
| Travel and Lodging | $32,017 | 71 | 18.4% |
| Consulting Fee | $16,550 | 8 | 9.5% |
| Food and Beverage | $5,391 | 87 | 3.1% |
| Unspecified | $1,530 | 2 | 0.9% |
Payments by Type
General
$172,119
215 transactions
Research
$1,530
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $79,535 | 81 | $0 (2023) |
| Horizon Therapeutics plc | $33,374 | 47 | $0 (2023) |
| Horizon Pharma plc | $22,930 | 34 | $0 (2018) |
| PTC Therapeutics, Inc. | $22,583 | 24 | $0 (2022) |
| Ipsen Biopharmaceuticals, Inc | $8,666 | 9 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $6,241 | 15 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $137.00 | 3 | $0 (2021) |
| Vertex Pharmaceuticals Incorporated | $85.41 | 1 | $0 (2018) |
| Sentynl Therapeutics, Inc. | $44.95 | 1 | $0 (2024) |
| Amicus Therapeutics, Inc. | $32.44 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,816 | 7 | Ipsen Biopharmaceuticals, Inc ($4,771) |
| 2023 | $9,391 | 17 | Horizon Therapeutics plc ($7,715) |
| 2022 | $22,485 | 18 | GENZYME CORPORATION ($19,929) |
| 2021 | $16,480 | 19 | GENZYME CORPORATION ($11,096) |
| 2020 | $13,920 | 15 | Horizon Therapeutics plc ($6,172) |
| 2019 | $55,302 | 69 | GENZYME CORPORATION ($23,350) |
| 2018 | $36,565 | 57 | Horizon Pharma plc ($22,930) |
| 2017 | $14,689 | 15 | Genzyme Corporation ($14,604) |
All Payment Transactions
217 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2024 | Sentynl Therapeutics, Inc. | Nulibry (Drug) | Food and Beverage | In-kind items and services | $44.95 | General |
| Category: Metal Metabolism/Inborn Errors | ||||||
| 09/21/2024 | Ipsen Biopharmaceuticals, Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,590.00 | General |
| 09/21/2024 | Ipsen Biopharmaceuticals, Inc | Sohonos (Drug) | Travel and Lodging | In-kind items and services | $1,062.92 | General |
| Category: Rare Disease | ||||||
| 09/21/2024 | Ipsen Biopharmaceuticals, Inc | Sohonos (Drug) | Travel and Lodging | In-kind items and services | $433.34 | General |
| Category: Rare Disease | ||||||
| 09/21/2024 | Ipsen Biopharmaceuticals, Inc | Sohonos (Drug) | Travel and Lodging | In-kind items and services | $361.06 | General |
| Category: Rare Disease | ||||||
| 09/21/2024 | Ipsen Biopharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $210.10 | General |
| 09/20/2024 | Ipsen Biopharmaceuticals, Inc | Sohonos (Drug) | Food and Beverage | In-kind items and services | $113.39 | General |
| Category: Rare Disease | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Honoraria | Cash or cash equivalent | $5,600.00 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Travel and Lodging | Cash or cash equivalent | $717.10 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Travel and Lodging | Cash or cash equivalent | $575.98 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Travel and Lodging | Cash or cash equivalent | $175.00 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Travel and Lodging | Cash or cash equivalent | $175.00 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Travel and Lodging | Cash or cash equivalent | $148.35 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $119.08 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $54.99 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $46.65 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $23.80 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $23.80 | General |
| Category: RAVICTI | ||||||
| 08/31/2023 | Ipsen Biopharmaceuticals, Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,480.00 | General |
| 07/25/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $35.91 | General |
| 06/28/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | In-kind items and services | $55.01 | General |
| Category: RAVICTI | ||||||
| 03/21/2023 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: Genetic Disease | ||||||
| 01/25/2023 | GENZYME CORPORATION | NEXVIAZYME (Biological) | Food and Beverage | In-kind items and services | $108.71 | General |
| Category: Genetic Disease | ||||||
| 01/24/2023 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Food and Beverage | In-kind items and services | $32.44 | General |
| Category: FABRY DISEASE | ||||||
| 08/25/2022 | GENZYME CORPORATION | FABRAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,763.00 | General |
| Category: Genetic Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Gaucher LSD Data Registry | GENZYME CORPORATION | $1,530 | 2 |
About Dr. Paldeep Atwal, MD
Dr. Paldeep Atwal, MD is a Clinical Genetics (M.D.) healthcare provider based in West Palm Beach, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/19/2012. The National Provider Identifier (NPI) number assigned to this provider is 1518201243.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paldeep Atwal, MD has received a total of $173,649 in payments from pharmaceutical and medical device companies, with $4,816 received in 2024. These payments were reported across 217 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($71,788).
Ad
Practice Information
- Specialty Clinical Genetics (M.D.)
- Other Specialties Clinical Genetics (M.D.), Clinical Biochemical Genetics
- Location West Palm Beach, FL
- Active Since 11/19/2012
- Last Updated 06/13/2024
- Taxonomy Code 207SG0201X
- Entity Type Individual
- NPI Number 1518201243
Products in Payments
- RAVICTI (Drug) $41,511
- FABRAZYME (Biological) $20,279
- CEREZYME (Drug) $18,819
- PROCYSBI (Drug) $14,418
- CERDELGA (Drug) $11,160
- LUMIZYME (Drug) $8,281
- FABRAZYME (Drug) $4,362
- BMN 165 (Drug) $3,725
- DISEASE STATE (Drug) $2,781
- Palynziq (Drug) $2,256
- Sohonos (Drug) $1,971
- LUMIZYME (Biological) $866.28
- NO_PRODUCT (Drug) $307.66
- Kuvan (Drug) $144.52
- Vimizim (Biological) $115.60
- NEXVIAZYME (Biological) $108.71
- ALDURAZYME (Biological) $87.56
- SYMDEKO (Drug) $85.41
- XLSD (Drug) $73.86
- Nulibry (Drug) $44.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.